Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
RYTM's Cash-to-Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RYTM: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
RYTM' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
RYTM's Interest Coverage is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RYTM: No Debt )
Ranked among companies with meaningful Interest Coverage only.
RYTM' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROA % -255.80
RYTM's ROA % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RYTM: -255.80 )
Ranked among companies with meaningful ROA % only.
RYTM' s ROA % Range Over the Past 10 Years
Min: -255.8  Med: -100.05 Max: -39.93
Current: -255.8
-255.8
-39.93
ROC (Joel Greenblatt) % -4780.65
RYTM's ROC (Joel Greenblatt) % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RYTM: -4780.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RYTM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -63082.35  Med: -46399.17 Max: -4780.65
Current: -4780.65
-63082.35
-4780.65
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RYTM's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with RYTM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: »  
Compare: » details
Traded in other countries:1RV.Germany,
Headquarter Location:USA
Rhythm Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders.

Rhythm Pharmaceuticals Inc was incorporated in November 2008. The Company is a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. Its product candidate, relamorelin, is a potent, Phase 2 ghrelin agonist for the treatment of diabetic gastroparesis, a GI complication of diabetes, and other GI functional disorders. It also is developing a second product candidate, RM-493, which is a potent, first-in-class, Phase 2 ready melanocortin-4, or MC4, receptor agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway.

Top Ranked Articles about Rhythm Pharmaceuticals Inc

Largest Insider Trades of the Week Facebook, Splunk among stocks sold by insiders
The GuruFocus All-In-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “October 2017” and All Insider Sales to “$5,000,000+." Read more...
Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Rhythm Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering

Ratios

vs
industry
vs
history
EV-to-EBIT -22.84
RYTM's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RYTM: -22.84 )
Ranked among companies with meaningful EV-to-EBIT only.
RYTM' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.19  Med: 0 Max: 0
Current: -22.84
-26.19
0
EV-to-EBITDA -22.98
RYTM's EV-to-EBITDA is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RYTM: -22.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
RYTM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.35  Med: 0 Max: 0
Current: -22.98
-26.35
0
Current Ratio 2.36
RYTM's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RYTM: 2.36 )
Ranked among companies with meaningful Current Ratio only.
RYTM' s Current Ratio Range Over the Past 10 Years
Min: 2.36  Med: 6.33 Max: 7.54
Current: 2.36
2.36
7.54
Quick Ratio 2.36
RYTM's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RYTM: 2.36 )
Ranked among companies with meaningful Quick Ratio only.
RYTM' s Quick Ratio Range Over the Past 10 Years
Min: 2.36  Med: 6.33 Max: 7.54
Current: 2.36
2.36
7.54

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -4.37
RYTM's Earnings Yield (Greenblatt) % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RYTM: -4.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RYTM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4.42  Med: 0 Max: 0
Current: -4.37
-4.42
0

More Statistics

EPS (TTM) $ -0.79
Short Percentage of Float0.00%
52-Week Range $22.60 - 33.81
Shares Outstanding (Mil)26.07

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}